The mission at Lipid Genomics is to use a personalized medicine approach to develop novel diagnostics and therapeutics for people with acute and chronic inflammatory diseases.

We have developed a companion diagnostic approach towards patients with deficiency of the immune checkpoint molecule, lymphocyte activation gene-3 (LAG3). We have shown that LAG3 deficiency is not rare and it significantly increases the risk of heart disease.  

With the arrival of LAG3 blocking antibodies for cancer treatment, we believe it is imperative that clinical oncologists become aware of LAG3 deficiency in their patients. 

Our patented LAG3 diagnostic test will identify oncology patients at increased risk for adverse events.   

​We have developed a patented recombinant LAG3 biologic as replacement therapy.  The recombinant LAG3 biologic is not an antibody.

The work being done at Lipid Genomics supports our passion to discover and develop new connections for better health.